NBIX Key Statistics, Chart & Performance
The current stock price of NBIX is 152.16 USD. In the past month the price increased by 10.23%. In the past year, price increased by 20.05%.
NBIX Latest News, Press Relases and Analysis
NBIX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About NBIX
Company Profile
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Company Info
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 1800
Phone: 18586177600
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What does NBIX do?
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
What is the stock price of NEUROCRINE BIOSCIENCES INC today?
The current stock price of NBIX is 152.16 USD. The price increased by 0.38% in the last trading session.
Does NBIX stock pay dividends?
NBIX does not pay a dividend.
How is the ChartMill rating for NEUROCRINE BIOSCIENCES INC?
NBIX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists NBIX stock?
NBIX stock is listed on the Nasdaq exchange.
What do analysts say about NEUROCRINE BIOSCIENCES INC (NBIX) stock?
35 analysts have analysed NBIX and the average price target is 177.35 USD. This implies a price increase of 16.55% is expected in the next year compared to the current price of 152.16.
Can you provide the sector and industry classification for NEUROCRINE BIOSCIENCES INC?
NEUROCRINE BIOSCIENCES INC (NBIX) operates in the Health Care sector and the Biotechnology industry.
NBIX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is one of the better performing stocks in the market, outperforming 80.15% of all stocks.
NBIX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NBIX. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
NBIX Financial Highlights
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 4.18. The EPS increased by 12.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.95% | ||
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| Debt/Equity | 0 |
NBIX Forecast & Estimates
35 analysts have analysed NBIX and the average price target is 177.35 USD. This implies a price increase of 16.55% is expected in the next year compared to the current price of 152.16.
For the next year, analysts expect an EPS growth of 53.46% and a revenue growth 21.48% for NBIX